KPV

Summary

KPV is three amino acids — lysine, proline, valine — and it is the tail end of alpha-MSH, the melanocyte-stimulating hormone, specifically residues 11 to 13. That is the entire molecule.

The research behind it is better than most things on this site. A 2008 paper in Gastroenterology showed KPV inhibits NF-κB and MAP-kinase inflammatory signalling at nanomolar concentrations in human intestinal epithelial and T cells, identified how it gets into those cells — through PepT1, a di/tripeptide transporter of the small intestine that becomes induced in the colon during inflammatory bowel disease — and showed that KPV in drinking water reduced colitis in two different mouse models. Work since has focused on gut-targeted oral delivery, including hyaluronic-acid nanoparticles and hydrogels.

Two facts constrain what that means for anyone buying it. No human study of KPV exists — the PubMed records tagged as clinical trials are false matches where "KPV" is somebody's initials. And the mechanism the good research is built on is an intestinal transporter, reached by mouth. Subcutaneous injection, the route most often sold, goes around it.

One more thing worth knowing: KPV is marketed as an α-MSH fragment acting on melanocortin receptors, and a 2003 study in the Journal of Pharmacology and Experimental Therapeutics concluded it is unlikely to work that way at all.

What people use it for

Gut inflammation — IBD, ulcerative colitis, Crohn's, "leaky gut" — is the use with the actual research behind it, and it is why KPV appears in gut-health protocols, usually alongside BPC-157.

Skin is the second: topical KPV is sold for acne, rosacea, eczema and general inflammation, on the strength of α-MSH's known presence in skin.

General anti-inflammatory and antimicrobial use rounds it out — KPV is often described as an anti-inflammatory that, unusually, does not suppress the immune response to infection.

Human evidence

There is none. We checked the way we check this: PubMed returns 53 records for KPV in a peptide context and 30 tagged as human, but the human-tagged records are cell-culture work using human cell lines — Caco2-BBE and HT29 intestinal epithelium, Jurkat T cells, keratinocytes, bronchial epithelial cells. Filtering for clinical-trial publication types returns seven records, and every one is a false match: a trial of menopausal gonadotropins, a New England Journal trial of erythropoietin in newborns, CT tumour-response studies. "KPV" in those is author initials or an unrelated abbreviation.

So nobody has published a study of what KPV does in a person, by any route, for any condition. Whatever the preclinical data suggests, the claim that it reduces inflammation or improves symptoms in people has not been tested. C.

Animal / preclinical evidence

This is where KPV earns its grades, and the work is genuinely good.

The colitis programme. The 2008 Gastroenterology study is the anchor. In human intestinal epithelial cells and human T cells stimulated with pro-inflammatory cytokines, nanomolar KPV inhibited NF-κB and MAP-kinase signalling and reduced pro-inflammatory cytokine secretion. Using radiolabelled KPV and competition experiments, the authors established that it enters cells via PepT1 — and PepT1's expression in the colon is induced by inflammatory bowel disease, meaning the transporter is most available exactly where the inflammation is. Then, orally, KPV in drinking water reduced the incidence of both DSS- and TNBS-induced colitis in mice, with lower pro-inflammatory cytokine expression.

Mechanism, transporter, cell data and two independent animal models is a properly constructed preclinical case. It is still mice and dishes, so A.

Subsequent work reinforces both the promise and the constraint. A 2017 Molecular Therapy study delivered KPV inside hyaluronic-acid-functionalized nanoparticles and efficiently alleviated ulcerative colitis in mice; a 2022 study used a KPV-binding hydrogel to restore the gut mucosal barrier in an inflamed colon. Notice what those papers are solving for: getting KPV to the inflamed gut. That engineering effort exists because free peptide does not reliably arrive on its own — which is a poor advertisement for a plain vial.

Antimicrobial activity. A 2000 study in the Journal of Leukocyte Biology found α-MSH and its C-terminal tripeptide KPV inhibited Staphylococcus aureus colony formation and reduced viability and germ-tube formation in Candida albicans, across a broad concentration range including picomolar. The effect appeared to run through increased cellular cAMP, since an adenylyl cyclase inhibitor partly reversed the killing. Notably, these peptides did not reduce neutrophil killing of the same pathogens — they enhanced it — which is the basis for the "anti-inflammatory without immunosuppression" description. All of this is in vitro. A.

Skin. The dermatological evidence is thinner than the marketing implies. A 2004 study characterised α-MSH, KPV and ACTH signalling in cultured human keratinocytes, and a 2025 study reported KPV mitigating fine-dust-induced keratinocyte apoptosis and inflammation, also in cell culture. Both are mechanism papers in dishes. We did not find an animal wound-healing model or a human skin study for KPV specifically. Cell-culture signalling is a reason to investigate, not a demonstration that a cream works, so the skin claim sits at B — below the gut and antimicrobial claims, which have animal or organism-level data behind them.

The receptor problem. KPV is sold as an α-MSH fragment, and melanocortin receptors are how α-MSH works, so the natural inference is that KPV is a small melanocortin agonist. A 2003 study tested that directly and found the opposite. In mouse peritonitis models, KPV reduced leukocyte accumulation — but its effect was not blocked by a melanocortin MC3/4 receptor antagonist, and it still worked in mice with a non-functional MC1 receptor. In macrophages, α-MSH and the MC3/4 agonist MTII inhibited activation and raised cAMP; KPV did neither. The authors concluded KPV's anti-inflammatory effect is clearly different from the core MSH peptides, is unlikely to be mediated through melanocortin receptors, and more likely works by inhibiting IL-1β.

This does not make KPV less interesting — it has a real anti-inflammatory effect by some route. It makes the standard explanation of how it works wrong, and that explanation is repeated in most product copy. C.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

KPV is usually reported on for gut symptoms, and almost always as part of a stack — most often with BPC-157, sometimes with glutamine or other gut-directed supplements. That makes attribution close to impossible even before the usual problems apply.

Community use also splits across three routes — oral capsules, subcutaneous injection, topical cream — which the research does not treat as interchangeable. The colitis data is oral and depends on an intestinal transporter; the skin data is cultured skin cells; the injectable route has no published counterpart at all. Reports pooled across all three are describing different exposures under one name.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

There is no human dose of KPV. There is no human study to have produced one.

The preclinical figures are less usable than they first appear. The 2008 colitis study administered KPV in the drinking water of mice and its abstract does not state a concentration; its cell-culture effects were at nanomolar concentrations, which describes what a cell sees in a dish, not what a person would swallow. The 2017 nanoparticle study delivered KPV inside a targeted carrier rather than as free peptide — the formulation is the intervention, so its dosing does not transfer to loose powder.

The route is the more important point. Every effective delivery in this literature is oral or gut-targeted, because the uptake mechanism identified in the anchor study is an intestinal transporter that IBD upregulates. Injecting KPV subcutaneously does not engage that pathway, and no published study has examined what it does instead.

Safety & side effects

KPV's safety in humans is unstudied, in the literal sense that no human study exists. What can be said is limited and should be read as such.

The theoretical case for tolerability is better than for most unapproved peptides: KPV is three common amino acids and a naturally occurring fragment of a hormone the body already makes, present in gut and skin. Preclinical work has not flagged toxicity, and the antimicrobial finding is unusual in a helpful direction — an anti-inflammatory that enhances rather than suppresses neutrophil killing of pathogens does not carry the infection risk that immunosuppressive anti-inflammatories do. That is a real point in its favour and it comes from a dish.

Against that: no human has been studied on it, so there is no data on dose, duration, route, drug interactions, or effects in any disease population — including the inflammatory bowel disease patients the research is aimed at, who are frequently on immunomodulating drugs. Anyone with IBD considering this should note that self-treating an inflammatory bowel condition with an unstudied compound instead of a monitored one is the specific risk here, and it is not a small one.

Material from research-chemical suppliers adds unverified identity, purity and sterility on top of all of the above.

Regulatory / legal status

KPV is not approved anywhere for anything — no FDA approval, no approval from any other regulator, no marketed pharmaceutical product, no prescription route, and no completed human trial. It is sold as research-chemical supply and, increasingly, in compounded oral and topical preparations. Compounded products are not FDA-approved, and no agency has evaluated any KPV preparation for safety or effectiveness.

We found no listing for KPV on the WADA Prohibited List; it is not a growth factor or a testosterone-stimulating peptide, which are the S2 categories that catch most compounds on this site. Absence from that list is not an endorsement and athletes should check current guidance directly rather than rely on this line.

Status can change and varies by country; this is not legal or medical advice.

Podcast / media mentions

KPV usually arrives in podcast and newsletter coverage as "the gut peptide" — the anti-inflammatory that fixes intestinal permeability, generally mentioned in the same breath as BPC-157 and generally with the Gastroenterology paper cited, correctly, as the evidence.

The paper is good, and citing it is fair. What the coverage drops is everything that determines whether it applies. It was mice and cell lines. The peptide was given by mouth. Its route into cells is an intestinal transporter that inflammatory bowel disease upregulates, which is a large part of why it works where it works. And the mechanism most often stated on air — that KPV is an α-MSH fragment hitting melanocortin receptors — was tested in 2003 and does not appear to be what happens.

The honest summary is that KPV is one of the more scientifically interesting compounds in this category, whose interesting data is oral, murine, and eighteen years old, and which nobody has yet given to a person in a study.